Results 21 to 30 of about 32,925 (256)

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics [PDF]

, 2018
Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters. Genetic polymorphisms that confer reduced CYP2D6 activity or concurrent use of CYP2D6-inhibiting drugs ...
Cronin-Fenton, Deirdre P, Damkier, Per
openaire   +4 more sources

CYP2D6‐Guided Opioid Therapy for Chronic Pain: A Multi‐Center Pragmatic Randomized Controlled Trial [PDF]

Clin Pharmacol Ther
The analgesic effectiveness of several opioids depends on CYP2D6‐mediated metabolism to more active opioid receptor agonists. CYP2D6 activity is impacted by genetic variability and medications that inhibit CYP2D6. We conducted a pragmatic, multi‐center, randomized, controlled trial to determine whether CYP2D6‐guided opioid prescribing improves chronic ...
Skaar T, Myers R, Fillingim R, Callaghan J, Cavanaugh K, Chakraborty H, Baye J, Cicali E, Eadon M, Elwood E, Harris E, Hines L, Nguyen K, Ramos M, Rosenman M, Sadeghpour A, Shuman S, Singh R, Tillman E, Wyatt C, Horowitz C, Voora D, Orlando L, Peterson J, Cavallari L, Johnson J, Dexter P.   +26 more
europepmc   +2 more sources

Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR [PDF]

Clinical Chemistry, 2000
Abstract Background: Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity.
Hersberger, Martin, Marti-Jaun, Jacqueline, Rentsch, Katharina, Hänseler, Edgar   +3 more
openaire   +3 more sources

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. [PDF]

, 2013
OBJECTIVE: To evaluate evidence on the association between CYP2D6 genotype and tamoxifen response through. DESIGN: Systematic review and meta-analysis of prospective, cross-sectional and case-control studies published to 2012.
Danny W. K. Lum, Perel, P, Aroon D. Hingorani (142610), Holmes, Michael V, Danny W. K. Lum (465585), Michael V. Holmes, Perel, Pablo, Holmes, MV, Aroon D Hingorani, Hingorani, AD, Michael V Holmes, Pablo Perel (102217), Hingorani, Aroon D, Danny W K Lum, Pablo Perel, Lum, Danny WK, Aroon D. Hingorani, Lum, DW, Michael V. Holmes (256443)   +18 more
core   +1 more source

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection [PDF]

, 2008
Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrhosis, often have severe consequences for the patient. Because of a lack of appropriate animal models, not much is known about their potential viral etiology. Infection
Hintereder, Gudrun, Gudrun Hintereder, Michael P. Manns, Christen, Urs, Herrath, Matthias G. von, Holdener, Martin, Monika Bayer, Johnson, Eric F., Urs Christen, Rodrigo, Evelyn, Frank J. Gonzalez, Pfeilschifter, Josef (Prof. Dr.), Eric F. Johnson, Evelyn Rodrigo, Gonzalez, Frank J., Martin Holdener, Edith Hintermann, Hintermann, Edith, Matthias von G. Herrath, Josef Pfeilschifter, Rhode, Antje, Bayer, Monika, Manns, Michael P., Antje Rhode   +23 more
core   +1 more source

Novel single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYP2D6*10 alleles

Drug Metabolism and Pharmacokinetics, 2002
Novel single nucleotide polymorphisms (SNPs) were found in introns 1, 3, 4, 5, and 7 of the gene encoding cytochrome (CYP) 2D6 in 90 Japanese subjects. Some of these SNPs were associated with C2850T and/or C100T, which are key SNPs for CYP2D6(*)2 and CYP2D6(*)10, respectively.
SOYAMA, Akiko, SAITO, Yoshiro, KOMAMURA, Kazuo, UENO, Kazuyuki, KAMAKURA, Shiro, OZAWA, Shogo, SAWADA, Jun-ichi   +6 more
openaire   +2 more sources

Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans [PDF]

, 2016
3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereoselective, with preference for S-stereoisomers. Its major metabolic step involves CYP2D6-catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by ...
Tingelhoff, Eva H., Eva H. Tingelhoff, Schmidhauser, Corina, Steuer, Andrea E, Yasmin Schmid (3181563), Eva H. Tingelhoff (3181572), Schmid, Yasmin, Tingelhoff, Eva H, Andrea E. Steuer (1712023), Anna Rickli (3181569), Yasmin Schmid, Anna Rickli, Thomas Kraemer (271037), Liechti, Matthias E., Matthias E Liechti, Liechti, Matthias E, Corina Schmidhauser, Andrea E. Steuer, Rickli, Anna, Matthias E. Liechti (166584), Eva H Tingelhoff, Thomas Kraemer, Andrea E Steuer, Corina Schmidhauser (3181566), Steuer, Andrea E., Matthias E. Liechti, Kraemer, Thomas, Rickli A, Kraemer T, Steuer AE, Schmidhauser C, Tingelhoff EH, Schmid Y, Liechti ME   +33 more
core   +1 more source

Substrate specificity of CYP2D6 genetic variants [PDF]

, 2021
Genetic variation in the gene encoding CYP2D6 is used to guide drug prescribing in clinical practice. However, genetic variants in CYP2D6 show substrate-specific effects that are currently not accounted for.
Guchelaar, H.J., Swen, J.J., Lee, M. van der, Maaike van der Lee, Jesse J Swen, Henk-Jan Guchelaar   +5 more
core   +1 more source

ผลของภาวะพหุสัณฐานของยีน CYP2D6 ต่อเภสัชจลนศาสตร์ของยาทาม็อกซิเฟนในผู้ป่วยไทยโรคมะเร็งเต้านม [PDF]

, 2011
Thesis (M.Sc.)--Chulalongkorn University, 2011The purposes of this study were to explore CYP2D6*10 allele frequency in Thai breast cancer patients and compare tamoxifen and its metabolites plasma concentration between patients with CYP2D6*1 and CYP2D6*10
Pichayapa Rungwanonchai
core   +1 more source

CYP2D6 gene polymorphism effect on central hemodynamic parameters in patients with portal hypertension taking propranolol

Медицинский совет, 2022
Introduction. Despite the huge number of modern recommendations for the treatment of patients with liver cirrhosis, there is still no clear scheme for prescribing non-selective beta-blockers.Aim. To evaluate effect of polymorphic markers CYP2D6*3, CYP2D6*
A. I. Parusov, I. D. Loranskaya, K. A. Akmalova, Zh. A. Sozaeva, O. L. Turkina, M. S. Zastrozhin, D. A. Sychev   +6 more
doaj   +1 more source